• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Alvotech

37.30 SEK

+0.67 %

Less than 1K followers

ALVO SDB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
+0.67 %
+22.09 %
+9.27 %
-19.68 %
-19.60 %
-55.06 %
-
-
-62.05 %

Alvotech is a biotechnology company that focuses on the development and manufacture of biosimilar medicines. The company's pipeline consists of biosimilar candidates aimed at treating autoimmune diseases, eye diseases, osteoporosis and cancer. The company offers its products to patients all over the world. Alvotech was founded in 2013 and has its headquarters in Reykjavík.

Read more
Market cap
12.93B SEK
Turnover
333.02K SEK
Revenue
5.39B
EBIT %
13.34 %
P/E
40.56
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
20/8
2026

Interim report Q2'26

12/11
2026

Interim report Q3'26

11/3
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release4 hours ago

Transactions of Managers and Closely Associated Persons

Alvotech
Regulatory press release6/18/2026, 8:00 AM

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Alvotech
Regulatory press release6/16/2026, 3:50 AM

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

Alvotech

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release6/15/2026, 8:01 PM

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech
Regulatory press release6/10/2026, 8:30 PM

Transactions of Managers and Closely Associated Persons

Alvotech
Regulatory press release6/8/2026, 8:00 AM

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

Alvotech
Regulatory press release6/4/2026, 8:00 AM

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Alvotech
Regulatory press release6/3/2026, 8:30 PM

Main Results of 2026 Annual and Extraordinary General Meeting

Alvotech
Regulatory press release6/2/2026, 8:30 PM

Alvotech to present at upcoming investor conferences in June

Alvotech
Regulatory press release6/1/2026, 8:30 AM

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

Alvotech
Regulatory press release5/11/2026, 8:30 AM

Alvotech announces completion of FDA surveillance inspection at Reykjavik facility

Alvotech
Regulatory press release5/6/2026, 8:30 PM

Alvotech Q1 2026 Financial Results

Alvotech
Regulatory press release4/30/2026, 8:30 PM

Alvotech Announces a Change in its Executive Team

Alvotech
Regulatory press release4/24/2026, 12:30 PM

Alvotech to Report Financial Results for the First Quarter of 2026

Alvotech
Regulatory press release3/30/2026, 11:57 PM

Alvotech files Annual Report with the SEC

Alvotech
Regulatory press release3/30/2026, 11:55 PM

Alvotech Publishes 2025 Annual Report

Alvotech
Regulatory press release3/18/2026, 10:15 PM

Alvotech Q4 2025 and Full Year 2025 Financial Results

Alvotech
Regulatory press release3/4/2026, 8:00 AM

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

Alvotech
Regulatory press release2/26/2026, 9:00 PM

Transactions of Managers and Closely Associated Persons

Alvotech
Regulatory press release2/11/2026, 4:00 PM

Alvotech Announces Increase in Number of Own Shares

Alvotech